Tempus AI, Inc. (TEM) — AI News Sentiment & Analysis

Third-quarter 2026 financial results, raised full-year guidance, and major biopharma collaborations. (Timing: Q4 2026 and full year 2026 outlook.)

Award of up to $9.5 million in ARPA-H funding for the ADVOCATE program. (Timing: Near-term development and multi-center study execution.)

Publication of the PRISM2 study in Nature Medicine, confirming best-in-class performance for cancer diagnostic and prognostic applications, reinforces Tempus AI's leadership and technological moat in precision medicine. (Timing: Ongoing (validates current strategy and future product development))

Collaboration to build one of the largest pediatric Acute Myeloid Leukemia (pAML) real-world data registries, leveraging Tempus's AI platforms (olivia, Lens) for precision medicine research. (Timing: Medium term (ongoing development and data generation, with research outcomes and commercialization potential evolving over more than 12 months).)

Tempus announced a strategic collaboration with Merck to enhance AI-driven precision medicine. This partnership could significantly improve patient outcomes by leveraging Tempus' data and AI capabilities. The collaboration opens up new growth opportunities for Tempus, making this a potential buying opportunity.

Launch of the novel HRD-RNA algorithm, improving patient identification for platinum-based chemotherapy or PARP inhibitors. (Timing: Clinical availability is expected later this year, providing a future milestone for stock re-rating.)